Section 01
What it's used for
Skin Trial Found No Real Difference
A small 13-person trial of copper peptide cream on laser-treated skin found no wrinkle difference versus plain cream, but patients liked it more. The famous '70% collagen boost' claim means 70% of people had some increase, not a 70% jump.
▸Clinical wording
A small double-blind trial (n=13) of a topical copper tripeptide complex on laser-resurfaced skin found no significant objective difference from control in wrinkles or overall skin quality, though patients reported greater satisfaction with the treated side. The often-cited "70% increase in collagen" figure traces to a non-PubMed-indexed study reporting that 70% of subjects showed some increase in collagen production, versus 50% and 40% for vitamin C and retinoic acid respectively — a responder rate, not a 70% magnitude of increase. No PubMed-indexed double-blind trial was found demonstrating GHK-Cu's superiority over vitamin C or retinol for photoaging.
Wound Healing: Animal Evidence Only
In rats, GHK-Cu increased collagen and repair molecules in an implanted wound chamber, but no study backs the popular '30% faster healing' claim. A separate rat study found it didn't boost blood vessel growth and led to more tissue death.
▸Clinical wording
In a rat subcutaneous wound-chamber model, GHK-Cu increased collagen and glycosaminoglycan deposition, but no publication was found reporting a "30% faster wound closure" figure. A separate rat study using an irradiated skin-flap model found topical GHK-Cu did not improve angiogenesis or VEGF expression and was associated with a larger ischemic area. No FDA-cleared wound-dressing product containing GHK-Cu was found, and the evidence for this direction is limited to animal models.
Hair Regrowth Claims Unproven
Claims that GHK-Cu regrows hair come only from sellers and online communities — no study tested it on hair growth phase, follicle size, or hair loss. The one related trial used a different, copper-free peptide, not compared to minoxidil.
▸Clinical wording
GHK-Cu's effects on hair are described in vendor and community material, but no published study was found evaluating GHK-Cu on anagen phase, follicle size, Wnt/beta-catenin signaling, or alopecia. The only related hair-growth trial identified tested a copper-free GHK peptide combined with 5-aminolevulinic acid, not GHK-Cu, and did not compare it to minoxidil.
Bone Claims Unproven, Lab Data Mixed
Claims that GHK-Cu heals bone come only from sellers and online communities — no animal or human study tested fracture healing or bone density. The one lab-dish study found it reduced two markers of bone-building cell activity.
▸Clinical wording
Claims that GHK-Cu promotes bone regeneration appear in vendor and community sources, but no in vivo fracture-healing or bone-density study of GHK-Cu was found in the published literature. The one relevant cell-culture study identified reported that GHK-Cu actually inhibited alkaline phosphatase and osteocalcin production in cultured osteoblasts, the opposite of a pro-osteoblast effect.
Brain Cell Protection Research
Researchers observed that GHK-Cu may protect brain cells by reducing oxidative damage, helping regulate iron and copper levels in the brain, and calming inflammation pathways linked to Alzheimer's and Parkinson's disease research.
▸Clinical wording
The peptide demonstrates neuroprotective effects including reduction of oxidative damage in neural tissue, modulation of iron and copper homeostasis in the brain, and suppression of neuroinflammatory pathways implicated in Alzheimer's and Parkinson's disease.
COPD Gene Activity Research
A gene-activity analysis suggests GHK-Cu might reverse harmful gene patterns seen in COPD, a chronic lung disease, turning up genes for tissue repair while turning down inflammation and tissue-destroying pathways.
▸Clinical wording
Gene expression analysis suggests GHK-Cu could reverse destructive gene expression patterns seen in COPD, upregulating tissue repair genes while suppressing inflammatory and tissue-destructive pathways.
Section 02
Mechanism of Action
Carrying copper to working enzymes
- The peptide acts as a delivery van, handing copper ions to enzymes that need them.
- Those enzymes handle antioxidant defence, collagen cross-linking and energy production inside cells.
- Researchers describe this copper delivery as the basis of its tissue repair and anti-ageing effects.
▸Clinical wording
Copper Delivery and Metalloenzyme Activation
GHK-Cu serves as a bioavailable copper delivery system, providing Cu²⁺ ions to critical metalloenzymes involved in tissue remodeling. It activates copper-dependent enzymes including superoxide dismutase (SOD), lysyl oxidase (essential for collagen and elastin cross-linking), and cytochrome c oxidase (mitochondrial electron transport). This copper delivery function is fundamental to its tissue repair and anti-aging effects.
Switching thousands of genes up or down
- In genome-wide studies a very low concentration changed the activity of 4,049 human genes.
- Genes for DNA repair, antioxidant defence, collagen building and stem-cell markers were turned up.
- Genes tied to inflammation, scarring and tissue breakdown were turned down at the same time.
▸Clinical wording
Gene Expression Reprogramming
Genome-wide studies reveal GHK-Cu modulates expression of 4,049 human genes at very low concentrations (1 μM). It upregulates genes involved in: DNA repair (XPC, ERCC3), antioxidant defense (TRX1, GPX), collagen synthesis (COL1A1, COL3A1), and stem cell markers. Simultaneously, it downregulates genes associated with inflammation (IL-6, TNF-α), fibrosis (TGF-β1), and tissue destruction (MMP-9, MMP-13).
Rebuilding the scaffolding under skin
- It raises production of collagen, elastin and the gel-like molecules that cushion tissue.
- It holds back the enzymes that break tissue down while boosting their natural blockers.
- This two-sided action pushes repair towards organised tissue rather than scar.
▸Clinical wording
Collagen and Extracellular Matrix Remodeling
GHK-Cu stimulates collagen synthesis (types I, III, and V), glycosaminoglycan production (decorin, versican), and elastin expression. It also regulates matrix metalloproteinases — suppressing destructive MMPs (MMP-1, 2, 9) while promoting constructive tissue remodeling through TIMP upregulation. This dual action promotes organized tissue repair rather than scarring.
Calming inflammation and mopping up damage
- The peptide lowers the signalling molecules that drive inflammation in tissue.
- Its copper complex directly neutralises reactive oxygen species, the unstable particles that damage cells.
- It also raises production of the body's own antioxidant enzymes.
▸Clinical wording
Anti-inflammatory and Antioxidant Activity
The peptide suppresses pro-inflammatory cytokines (TNF-α, IL-6, IL-1β) and TGF-β signaling while enhancing antioxidant gene expression. It directly scavenges reactive oxygen species through its copper complex and upregulates endogenous antioxidant enzymes (SOD1, SOD3, glutathione peroxidase).
Calling repair cells to damaged tissue
- Chemical signals draw regenerative stem cells towards sites of tissue damage.
- It pushes mesenchymal stem cells, a repair cell type, towards becoming mature tissue.
- It also activates the stem cells already living in skin, hair follicles and other organs.
▸Clinical wording
Stem Cell Recruitment
GHK-Cu promotes the attraction of regenerative stem cells to sites of tissue damage through chemotactic signaling. It enhances mesenchymal stem cell differentiation and activates resident tissue stem cells in skin, hair follicles, and other organs.
Section 03
Biological Pathways
- TGF-β/Smad Signaling ModulationDownregulates TGF-β1 signaling and Smad3 phosphorylation while promoting inhibitory Smad7, shifting healing from fibrotic to regenerative and reducing scarring.
- Wnt/β-catenin PathwayActivated via upregulated Wnt ligands and Frizzled receptors, promoting stem cell self-renewal, hair follicle neogenesis, and tissue regeneration.
- Nrf2/ARE Antioxidant DefenseActivates the Nrf2 transcription factor, driving phase II detoxification enzymes and antioxidant proteins via the ARE for protection against oxidative stress.
- Notch SignalingModulated to support stem cell differentiation and tissue homeostasis, particularly relevant to skin renewal and hair follicle cycling.
Section 04
Dosage Information
GHK-Cu| Route / system | Context | Range studied | Limitation |
|---|---|---|---|
| Topical — face | Creams; 12-week controlled trials, 71 and 41 women | 0.05–2% GHK-Cu in a leave-on product; most serums 0.1–1%, eye products 0.1–0.5%. The trials never published their own concentration. | No percentage on a label can be traced back to those trials. Above 2% the complex needs stability testing that brands do not publish. |
| Topical — scalp | Hair and scalp products; formulator guidance | 1–3% GHK-Cu in leave-on scalp solutions; formulators treat 3% as the ceiling before irritation starts. | These come from formulators, not a trial. No controlled hair-growth trial has been published, and nothing shows it reaches the hair root at all. |
| Subcutaneous — self-administration | Circulating practice, not a finding | 1–2 mg per day is the figure that circulates — roughly 11–29 µg/kg for a 70–90 kg adult. | No trial has ever dosed injected GHK-Cu — no dose finding, nothing measured in blood, no safety study. The wound drug Iamin was never approved. |
| Subcutaneous — copper load | Adult dietary copper limits, applied to an injection | Copper is about 16% of GHK-Cu by mass (403.9 g/mol), so 1–2 mg carries 160–310 µg. The daily norm is 900 µg, the upper limit 10 mg. | Those limits cover swallowed copper, whose absorption the gut controls. Injection bypasses that, and its effect on blood and liver copper was never measured. |
Results
Syringe Fill Level (100u syringe)
Set positive values for: Recommended dose per kg.
Research Use Only. This information is for educational and research purposes only. Not intended for medical advice or self-medication.
Section 05
Protocols
- Protocol 01
Anti-Aging Skincare Peptide Stack
Topical peptide protocol for wrinkle reduction, collagen stimulation, and skin rejuvenation.
- Focus
- Skin & Beauty
- Level
- Beginner
- Duration
- 8–12 weeks
- Protocol 02
GHK-Cu Hair Growth Protocol
Copper peptide protocol for hair regrowth and scalp health.
- Focus
- Skin & Beauty
- Level
- Intermediate
- Duration
- 6–12 months
Section 06
Stability & Storage
Lyophilised powder
Supplied as a blue-tinted lyophilised powder — the colour comes from the copper complex — and kept at -20 °C for long-term storage (2+ years) or at 2-8 °C, where it stays stable for 12 months. It is protected from light and moisture. For injectable use it is reconstituted with bacteriostatic water.
After reconstitution
The reconstituted solution is kept at 2-8 °C and used within 21 days. Copper binding makes this complex more stable than the free GHK tripeptide by protecting it against peptidase degradation, so strong chelating agents such as EDTA are avoided, as they can strip the copper ion.
Section 07
Side Effects & Precautions
GHK-Cu is generally well-tolerated topically, with mild irritation in sensitive individuals and rare allergic reactions; it also has injection-site reactions, theoretical risks at very high copper doses, a cancer-growth question, and interactions for people on copper chelation therapy.
Topical use (generally well-tolerated)
Topical use has been evaluated in multiple clinical trials, with mild skin irritation, temporary redness, or tingling reported in sensitive individuals, typically resolving within hours, and allergic reactions described as rare.
Injection site reactions
When given subcutaneously, mild pain, redness, and temporary discoloration (blue-green, from the copper) at the injection site have been reported.
Copper-related effects at high doses
At very high systemic doses, far exceeding typical use, copper accumulation could theoretically cause nausea, vomiting, or liver toxicity (hepatotoxicity). This is described as not a concern at normal peptide doses (1-5 mg per day), since GHK-Cu provides only microgram quantities of copper.
Theoretical cancer-growth concerns
As with other growth-promoting peptides, there is a theoretical concern about stimulating growth in existing malignancies. Gene expression studies, however, show GHK-Cu raises tumor-suppressor gene activity (p53, PTEN) and lowers metastasis-gene activity, a pattern described as net anticancer.
Drug and supplement interactions
GHK-Cu is not suitable for people receiving copper chelation therapy (penicillamine, trientine) for Wilson's disease. The same applies to people who take other copper-containing supplements at the same time.
Section 08
Regulatory Status
Applied to skin, it is a lawfully marketed cosmetic ingredient sold in thousands of products; given by injection, the same molecule is an unapproved, investigational drug substance with its own FDA compounding history.
Cosmetic ingredient / United States
No pre-market approval required
The FDA does not clear or approve cosmetic ingredients before sale, and GHK-Cu (copper tripeptide-1) is sold this way in skincare; some wound-care dressings containing it hold separate FDA medical-device clearance, a different track from drug approval.
Cosmetic ingredient / EU
Regulated as a cosmetic, not a drug
Under Regulation (EC) 1223/2009 GHK-Cu is listed by its INCI name «Copper Tripeptide-1» with no concentration limit, the standard route for cosmetic actives rather than pharmaceuticals.
Injectable form / FDA
Investigational, review pending
In 2023 the FDA assigned injectable GHK-Cu to Category 2 of the interim 503A bulk-substances list and lifted that listing in April 2026 after the nomination was withdrawn; a Pharmacy Compounding Advisory Committee review is planned before February 2027. Removal from Category 2 is not addition to the 503A Bulks List — injectable GHK-Cu is not on that list, so no lawful compounding route is open.
WADA
Not on the prohibited list
GHK-Cu does not appear on the 2026 Prohibited List, though athletes should recheck before use since the list is updated every year.
A cosmetic-ingredient listing says nothing about the safety or legality of injecting the same compound, and rules differ between the two uses and between jurisdictions — check current sources before relying on any of this.
Section 09
Research Studies
- [1]GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin RegenerationPickart L, Vasquez-Soltero JM, Margolina A. · BioMed Research International · 2015
- [2]GHK-Cu may Prevent Oxidative Stress in Skin by Regulating Copper and Modifying Expression of Numerous Antioxidant GenesPickart L, Vasquez-Soltero JM, Margolina A. · Cosmetics · 2015
- [3]Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene DataPickart L, Margolina A. · International Journal of Molecular Sciences · 2018
- [4]A gene expression signature of emphysema-related lung destruction and its reversal by the tripeptide GHKCampbell JD, McDonough JE, Zeskind JE, et al. · Genome Medicine · 2012
- [5]In vivo stimulation of connective tissue accumulation by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+ in rat experimental woundsMaquart FX, Bellon G, Chaqour B, et al. · Journal of Clinical Investigation · 1993
- [6]Expression of Glycosaminoglycans and Small Proteoglycans in Wounds: Modulation by the Tripeptide-Copper Complex Glycyl-L-Histidyl-L-Lysine-Cu2+Simeon A, Wegrowski Y, Bontemps Y, Maquart FX. · Journal of Investigative Dermatology · 2000
- [7]The effect of tripeptide-copper complex on human hair growth in vitroPyo HK, Yoo HG, Won CH, et al. · Archives of Pharmacal Research · 2007
- [8]Stem cell recovering effect of copper-free GHK in skinChoi HR, Kang YA, Ryoo SJ, et al. · Journal of Peptide Science · 2012
- [9]GHK Peptide Inhibits Bleomycin-Induced Pulmonary Fibrosis in Mice by Suppressing TGFbeta1/Smad-Mediated Epithelial-to-Mesenchymal TransitionZhou XM, Wang GL, Wang XB, et al. · Frontiers in Pharmacology · 2017
- [10]Effect of Gly-Gly-His, Gly-His-Lys and their copper complexes on TNF-alpha-dependent IL-6 secretion in normal human dermal fibroblastsGruchlik A, Jurzak M, Chodurek E, Dzierzewicz Z. · Acta Poloniae Pharmaceutica · 2012
Section 10
Frequently Asked Questions
The evidence is thinner than the marketing suggests. The one small double-blind trial identified — 13 patients, on laser-resurfaced skin — found no significant objective difference from control in wrinkles or skin quality, though patients said they preferred the treated side. The widely repeated '70% increase in collagen' figure comes from a study not indexed on PubMed, and it actually reports that 70% of subjects showed some increase in collagen — a responder rate, not a 70% magnitude — versus 50% for vitamin C and 40% for retinoic acid. No indexed double-blind trial shows GHK-Cu outperforming vitamin C or retinol for sun-damaged skin.
There is no published study evaluating GHK-Cu itself for hair growth, follicle size, or alopecia. The one related trial that exists tested a different, copper-free GHK peptide combined with 5-aminolevulinic acid — not GHK-Cu — and it was not compared against minoxidil. Hair-growth claims for GHK-Cu in circulation are not backed by a study of the actual compound.
No oral pharmacokinetic or efficacy data for GHK-Cu appears in the published research — the documented studies cover only topical application in cosmetic trials and, separately, unstudied self-administered injection. As a copper-binding tripeptide, its stability and absorption after swallowing have not been established; oral GHK-Cu products are not supported by a specific study of the compound taken by mouth.
This is not explained in the published research — no study measured or investigated why injected GHK-Cu causes stinging. What is documented is that subcutaneous injection is associated with mild site pain, redness, and temporary blue-green discoloration from the copper itself; injected GHK-Cu has never been through a formal dose-finding or safety trial, so this reaction has not been formally characterized beyond self-reports.
Topically, GHK-Cu has a good safety record across trials: mild irritation, redness, or tingling in sensitive skin that usually resolves within hours, with rare allergic reactions. Injected, the reported effects are mild site pain, redness, and temporary blue-green discoloration from the copper itself. Very high systemic copper exposure could theoretically cause nausea, vomiting, or liver toxicity, though this is not described as a concern at typical peptide-range doses; people on copper-chelation therapy for Wilson's disease are advised to avoid it.
As a topical cosmetic ingredient, GHK-Cu is legal and widely used — it has GRAS status for cosmetic use in the US, appears in FDA-cleared wound-care products, and is an approved EU cosmetic ingredient (INCI name Copper Tripeptide-1) with no concentration limit. Injectable GHK-Cu is a different matter: it remains an investigational compound with no approved pharmaceutical use. It is not on WADA's prohibited list, though athletes are advised to verify current regulations themselves.
The lyophilised powder — blue-tinted from the copper — stores for 2+ years at -20 °C or 12 months at 2-8 °C, protected from light and moisture. Once reconstituted for injectable use, the solution is kept at 2-8 °C and used within 21 days; strong chelating agents like EDTA should be avoided since they can strip the copper out of the complex.